Can Sitagliptin reduce inflammation in diabetes-related complications, and what pathways are involved in this anti-inflammatory effect?
Share
IVF Questions & Answers
Sign Up to our social questions and Answers Engine to ask questions, answer people’s questions, and connect with other people.
Please briefly explain why you feel this question should be reported.
Please briefly explain why you feel this answer should be reported.
Please briefly explain why you feel this user should be reported.
Can Sitagliptin reduce inflammation in diabetes-related complications, and what pathways are involved in this anti-inflammatory effect?
Sitagliptin can reduce inflammation in diabetes-related complications by inhibiting the DPP-4 enzyme and enhancing GLP-1 activity, which suppresses pro-inflammatory cytokines.
Sitagliptin mitigates inflammation in diabetes by modulating the DPP-4/GLP-1 pathway, leading to decreased expression of inflammatory markers like TNF-alpha and IL-6.